Ross Moat compensation by year
Kiniksa Pharmaceuticals International Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $436,581 | $511,596 | $586,269 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $183,811 | $468,219 | $1,084,019 |
| Option awards | $742,178 | $1,059,134 | $1,356,609 |
| Non-equity incentive | $243,141 | $287,773 | $533,326 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $25,497 | $10,407 | $77,778 |
| Total | $1,631,209 | $2,337,130 | $3,638,001 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 16, 2026, accession 0001104659-26-044410, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Kiniksa Pharmaceuticals International, plc filed document, accession 0001104659-26-044410. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 19,657 | $810,851 | — |
| RSU | 9,828 | $405,405 | — |
| PSU | 5,569 | $229,721 | — |
| PSU | 5,225 | $215,531 | — |
| RSU | 5,221 | $215,366 | — |
| PSU | 4,976 | $205,260 | — |
| RSU | 3,222 | $132,908 | — |
| RSU | 2,477 | $102,176 | — |
| Option | 21,058 | — | $18.06 |
| Option | 39,364 | — | $21.77 |
| Option | 16,916 | — | $17.76 |
| Option | 4,954 | — | $11.10 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Kiniksa Pharmaceuticals International, plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.
Insider transactions since the last proxy
40 Form 4 lines since the FY2025 proxy (filed April 16, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-02 | Exercise or conversion derivative | 10b5-1 | 12,302 | $0.00 | 27,062 |
| 2026-11-02 | Exercise or conversion | 10b5-1 | 6,263 | $22.89 | 38,271 |
| 2026-11-02 | Sale | 10b5-1 | 722 | $94.05 | 10,294 |
| 2026-11-02 | Exercise or conversion derivative | 10b5-1 | 9,412 | $0.00 | 15,793 |
| 2026-11-02 | Exercise or conversion | 10b5-1 | 9,412 | $18.06 | 19,706 |
| 2026-11-02 | Exercise or conversion | 10b5-1 | 12,302 | $21.77 | 32,008 |
| 2026-11-02 | Sale | 10b5-1 | 8,932 | $92.05 | 22,658 |
| 2026-11-02 | Sale | 10b5-1 | 6,681 | $91.23 | 31,590 |
The 8 most recent of 40 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Kiniksa Pharmaceuticals International’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sanj Patel | Chief Executive Officer and Chairman of the Board | $10,782,661 |
| Ross Moat · this page | Executive Vice President and Chief Commercial Officer | $3,638,001 |
| John Paolini | Executive Vice President and Chief Medical Officer | $3,570,655 |
| Eben Tessari | Executive Vice President and Chief Operating Officer | $3,566,231 |
| Mark Ragosa | Senior Vice President and Chief Financial Officer | $3,283,055 |
Ross Moat's compensation dossier, Kiniksa Pharmaceuticals International
You have read Ross Moat's totals and holdings. The dossier adds each equity grant Kiniksa Pharmaceuticals International disclosed for Ross Moat and Kiniksa Pharmaceuticals International's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Kiniksa Pharmaceuticals International compensation record
free company briefThis page is one person within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Kiniksa Pharmaceuticals International proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Kiniksa Pharmaceuticals International's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kiniksa Pharmaceuticals International's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order KNSA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.